SAN DIEGO--(BUSINESS WIRE)--Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent Number 7,375,111 with broad claims covering sustained release (SR) compositions of bupropion and naltrexone combined in a single dosage form. These two drugs are the active constituents in Contrave®, the Company’s lead obesity product candidate, now in Phase III clinical trials. Naltrexone SR, a proprietary formulation developed by Orexigen, was designed to improve patient tolerability by altering the pharmacokinetic profile of the original product.
